Amid fluctuating market conditions, Wedbush analyst Dan Ives has shed light on the pivotal role Elon Musk plays in the performance of Tesla Inc. stock.
Inflationary environment should not come as a surprise given the growth momentum, loose financing condition and depressed jobless rate, says Larry Summers.
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections and strategic initiatives, Amphastar aims to capitalize on emerging opportunities in the endocrinology sector for continued growth.
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.